Tumour hypoxia imaging with 18F-fluoroazomycinarabinofuranoside PET/CT in patients with locally advanced rectal cancer

Havelund, Birgitte Mayland; Holdgaard, Paw; Rafaelsen, Søren Rafael; Mortensen, Lise Saksø; Theil, Jørn; Bender, Dirk; Pløen, John; Spindler, Karen‐Lise Garm; Jakobsen, Anders

doi:10.1097/mnm.0b013e32835bd5bc

Cited by 38 publications

(31 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Reischl et al [165] , Piert et al [166] , Picchio et al [167] , Maier et al [168] , Tran et al [169] Barthel et al [187] Busk et al [170] , Mortensen et al [171] , Piert et al [166] , Tran et al [169] Barthel et al [187] Busk et al [170] , Busk et al [172] , Busk et al [173] , Busk et al [174] , Busk et al [175] , Graves et al [176] , Maier et al [168] , Solomon et al [177] NA Belloli et al [178] , Picchio et al [167] , Troost et al [179] , Valtorta et al [143] NA Sorger et al [57] , Piert et al [166] , Reischl et al [165] Rasey et al [188] Postema et al [180] , Bollineni et al [181] , Trinkaus et al [58] , Verwer et al [59] NA Grosu et al [182] , Souvatzoglou et al [183] , Schuetz et al [184] , Shi et al [106] , Mortensen et al [185] , Havelund et al [186] NA…”

Section: F]ef5mentioning

confidence: 99%

Positron emission tomography to assess hypoxia and perfusion in lung cancer

Verwer

Boellaard

Veldt

2014

WJCO

View full text Add to dashboard Cite

Core tip:This review provides an overview of the current applications of positron emission tomography for hypoxia and perfusion imaging in lung cancer. Available PET tracers are discussed and the benefits of combined hypoxia and perfusion PET imaging are clarified. Hypoxia imaging could aid in selecting patients for hypoxia-specific treatment strategies. To achieve this, consensus about the optimal imaging protocol and quantification method is essential. Large clinical trials are needed to confirm the value of hypoxia imaging for improving patient care.Verwer EE, Boellaard R, van der Veldt AAM. Positron emission tomography to assess hypoxia and perfusion in lung cancer.

show abstract

Section: F]ef5mentioning

confidence: 99%

Positron emission tomography to assess hypoxia and perfusion in lung cancer

Verwer

Boellaard

Veldt

2014

WJCO

View full text Add to dashboard Cite

show abstract

“…In particular, 18 F-FAZA has been proposed, and its hypoxia-specific uptake mechanism has been demonstrated (5). The advantage of 18 F-FAZA over 18 F-FMISO seems related mainly to its kinetic properties (9), and it has been shown to be particularly promising for clinical purposes (10)(11)(12)(13).…”

mentioning

confidence: 99%

First Evaluation of PET-Based Human Biodistribution and Dosimetry of ¹⁸F-FAZA, a Tracer for Imaging Tumor Hypoxia

et al. 2017

View full text Add to dashboard Cite

18 F-labeled fluoroazomycinarabinoside ( 18 F-FAZA) is a PET biomarker for noninvasive identification of regional tumor hypoxia. The aim of the present phase I study was to evaluate the biodistribution and dosimetry of 18 F-FAZA in non-small cell lung cancer patients. Methods: Five patients awaiting surgical resection of histologically proven or radiologically suspected non-small cell lung cancer were prospectively enrolled in the study. The patients underwent PET/CT after injection of 371 6 32 MBq of 18 F-FAZA. The protocol consisted of a 10-min dynamic acquisition of the heart to calculate the activity in blood, followed by 4 whole-body PET/CT scans, from the vertex to the mid thigh, at 10, 60, 120, and 240 min after injection. Urine samples were collected after each imaging session and at 360 min after injection. Volumes of interest were drawn around visually identifiable source organs to generate time-activity curves. Residence times were determined from time-activity curves, and effective doses to individual organs and the whole body were calculated using OLINDA/EXM 1.2 for the standard male and female phantoms. Results: Blood clearance was characterized by a rapid distribution followed by first-order elimination. The highest uptake was in muscle and liver, with respective percentage injected activity (%IA) peaks of 42.7 6 5.3 %IA and 5.5 6 0.6 %IA. The total urinary excretion was 15 %IA. The critical organ, with the highest absorbed radiation doses, was the urinary bladder wall, at 0.047 6 0.008 and 0.067 6 0.007 mGy/ MBq for the 2-and 4-h voiding intervals, respectively. The effective doses for the standard male and female phantoms were 0.013 6 0.004 and 0.014 6 0.004 mSv/MBq, respectively, depending on the voiding schedule. Conclusion: With respect to the available literature, the biodistribution of 18 F-FAZA in humans appeared to be slightly different from that in mice, with a low clearance in humans. Therefore, use of animal data may moderately underestimate radiation doses to organs in humans. Our dosimetry data showed that a 370-MBq injection of 18 F-FAZA is safe for clinical use, similar to other widely used PET ligands. In particular, the effective dose is not appreciably different from those obtained with other hypoxia tracers, such as 18 F-fluoromisonidazole.

show abstract

“…In addition, mapping of hypoxic tumor areas may enable specific targeting of hypoxic tumor tissue with intensified radiation therapy (7)(8)(9). 18 F-fluoroazomycinarabinoside ( 18 F-FAZA) is a promising hypoxia-specific PET tracer (10)(11)(12)(13)(14)(15) that is based on a nitroimidazole group and that undergoes electron reduction when it enters cells. Under normoxic conditions, this process is followed by reoxygenation and transport from the cell.…”

mentioning

confidence: 99%

Parametric Methods for Quantification of ¹⁸F-FAZA Kinetics in Non–Small Cell Lung Cancer Patients

et al. 2014

View full text Add to dashboard Cite

18 F-fluoroazomycinarabinoside ( 18 F-FAZA) is a hypoxia-specific PET tracer. In future clinical applications of hypoxia imaging, such as early response monitoring or radiation therapy dose painting, accurate quantification of tracer uptake at the voxel level will be required. The aim of the present study was to assess the validity of parametric methods for the quantification of 18 F-FAZA studies. Methods: Dynamic 70-min 18 F-FAZA scans were obtained from 9 non-small cell lung cancer patients. Arterial blood samples, collected at 7 time points, were used for preprocessing an imagederived input function derived from volumes of interest (VOIs) defined within the ascending aorta. Time-activity curves derived from various tumor VOIs were fitted using nonlinear regression analysis (NLR) to a reversible 2-tissue-compartment model, providing volumes of distribution (V T ) as an outcome measure. Next, parametric images were generated by use of both Logan graphic analysis with various linear regression start times and spectral analysis with multiple sets of basis functions. The previously defined tumor VOIs were projected onto these parametric images, and the resulting V T were compared with those obtained from NLR. In addition, the results were compared with tumor-to-blood ratios (SUVr), which are more easily obtainable. Results: The highest correlations and correspondence with NLR-derived V T were found for Logan graphic analysis with a start time of 30 min after injection (R 2 , 0.88; intraclass correlation coefficient [ICC], 0.93) and for spectral analysis-derived V T with a set of 30 basis functions with exponents ranging from 0.0175 to 1.9 (R 2 , 0.79; ICC, 0.81). SUVr yielded similar correlations but showed significant bias at high V T (R 2 , 0.85; ICC, 0.80). Conclusion: Both Logan graphic analysis and spectral analysis yielded V T that showed high correlations with nonlinear regression analysis-derived V T . SUVr showed bias at high V T .

show abstract

Tumour hypoxia imaging with 18F-fluoroazomycinarabinofuranoside PET/CT in patients with locally advanced rectal cancer

Abstract: F-FAZA PET/CT is feasible for visualization of hypoxia in patients with rectal cancer, but scattered activity from the urinary bladder should be taken into consideration.

Cited by 38 publications

References 19 publications

Positron emission tomography to assess hypoxia and perfusion in lung cancer

Positron emission tomography to assess hypoxia and perfusion in lung cancer

First Evaluation of PET-Based Human Biodistribution and Dosimetry of ¹⁸F-FAZA, a Tracer for Imaging Tumor Hypoxia

Parametric Methods for Quantification of ¹⁸F-FAZA Kinetics in Non–Small Cell Lung Cancer Patients

Contact Info

Product

Resources

About

Tumour hypoxia imaging with 18F-fluoroazomycinarabinofuranoside PET/CT in patients with locally advanced rectal cancer

Abstract: F-FAZA PET/CT is feasible for visualization of hypoxia in patients with rectal cancer, but scattered activity from the urinary bladder should be taken into consideration.

Cited by 38 publications

References 19 publications

Positron emission tomography to assess hypoxia and perfusion in lung cancer

Positron emission tomography to assess hypoxia and perfusion in lung cancer

First Evaluation of PET-Based Human Biodistribution and Dosimetry of 18F-FAZA, a Tracer for Imaging Tumor Hypoxia

Parametric Methods for Quantification of 18F-FAZA Kinetics in Non–Small Cell Lung Cancer Patients

Contact Info

Product

Resources

About

First Evaluation of PET-Based Human Biodistribution and Dosimetry of ¹⁸F-FAZA, a Tracer for Imaging Tumor Hypoxia

Parametric Methods for Quantification of ¹⁸F-FAZA Kinetics in Non–Small Cell Lung Cancer Patients